Filtered By:
Condition: Bleeding
Education: Study
Countries: Japan Health

This page shows you your search results in order of date.

Order by Relevance | Date

Total 187 results found since Jan 2013.

Improve Your Memory A Whopping 27%
Traditional doctors think the best way to treat memory loss is with Big Pharma’s latest “breakthrough” drug. And when it’s proven not to work – not to mention dangerous – they simply pull another one out of their pocket… That’s why I’m so concerned about the media buzz surrounding Lecanemab, one of the latest FDA-approved Alzheimer’s drug. Because I want to be clear: It is NOT a wonder drug. Lecanemab is a pharmaceutical product that, in clinical trials, resulted in a slight decline in cases of early Alzheimer’s when compared to a placebo. But…it was also associated with a long list of extremel...
Source: Al Sears, MD Natural Remedies - August 25, 2023 Category: Complementary Medicine Authors: Jacob Tags: Anti-Aging Source Type: news

Relationship Between Direct Oral Anticoagulant Doses and Clinical Outcomes in Elderly Patients With Non-Valvular Atrial Fibrillation 　- ANAFIE Registry Sub-Analysis
CONCLUSIONS: Inappropriate low DOAC doses (under- or off-label dose) were not associated with stroke/SEE or major bleeding but were associated with all-cause death.PMID:37482411 | DOI:10.1253/circj.CJ-23-0143
Source: Circulation Journal - July 23, 2023 Category: Cardiology Authors: Masaharu Akao Hiroshi Inoue Takeshi Yamashita Hirotsugu Atarashi Takanori Ikeda Yukihiro Koretsune Ken Okumura Shinya Suzuki Hiroyuki Tsutsui Kazunori Toyoda Atsushi Hirayama Masahiro Yasaka Takenori Yamaguchi Satoshi Teramukai Tetsuya Kimura Yoshiyuki Mo Source Type: research

Characteristics and short-term outcomes of outpatient and inpatient cardiac catheterizations: A descriptive study using a nationwide claim database in Japan
CONCLUSIONS: Approximately 5 % of cardiac catheterizations were performed in an outpatient setting. Given the low adverse event risk observed in this study, it may be a reasonable option to widen outpatient cardiac catheterization to include potential populations in Japan, warranting further studies.PMID:37247658 | DOI:10.1016/j.jjcc.2023.05.010
Source: Journal of Cardiology - May 29, 2023 Category: Cardiology Authors: Nao Setogawa Hiroyuki Ohbe Toshiaki Isogai Hiroki Matsui Hideo Yasunaga Source Type: research

Frailty and subsequent adverse outcomes in older patients with atrial fibrillation treated with oral anticoagulants: The Shizuoka study
CONCLUSION: Patients with frailty in whom OAC therapy is initiated have higher risk of bleeding, highlighting the importance of discussing this increased risk with patients with AF who have frailty and assessing frailty at the time of OAC initiation.PMID:37168397 | PMC:PMC10165150 | DOI:10.1016/j.rpth.2023.100129
Source: Thrombosis and Haemostasis - May 11, 2023 Category: Hematology Authors: Shiori Nishimura Hiraku Kumamaru Satoshi Shoji Eiji Nakatani Hiroyuki Yamamoto Nao Ichihara Alexander T Sandhu Yoshiki Miyachi Hiroaki Miyata Shun Kohsaka Source Type: research

Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants
AbstractLarge-scaled post-marketing surveillance studies (PMSSs) of 4 direct oral anticoagulants (DOACs) for stroke prevention in non-valvular atrial fibrillation (AF) were conducted since 2011 in Japan, and the results of the last one have recently been published. Each reported a more than acceptable ischemic stroke prevention. The major bleeding rates were also acceptably low and comparable to each other in the PMSSs of dabigatran (J-dabigatran), rivaroxaban (XAPASS), and edoxaban (ETNA-AF-Japan). However, the incidence in PMSS of apixaban (STANDARD) was more than double the others. This finding appeared to contradict th...
Source: European Journal of Clinical Pharmacology - April 25, 2023 Category: Drugs & Pharmacology Source Type: research

Registry for Evaluating Healthy Life Expectancy and Long-Term Outcomes after Catheter Ablation of Atrial Fibrillation in the Very Elderly (REHEALTH AF) study: rationale and design of a prospective, multicentre, observational, comparative study
Introduction Data are lacking on the extent to which patients with non-valvular atrial fibrillation (AF) who are aged ≥80 years benefit from ablation treatment. The question pertains especially to patients’ postablation quality of life (QoL) and long-term clinical outcomes. Methods and analysis We are initiating a prospective, registry-based, multicentre observational study that will include patients aged ≥80 years with non-valvular AF who choose to undergo treatment by catheter ablation and, for comparison, such patients who do not choose to undergo ablation (either according to their physician’s advice...
Source: BMJ Open - February 15, 2023 Category: General Medicine Authors: Okumura, Y., Nagashima, K., Watanabe, R., Yokoyama, K., Kato, T., Fukaya, H., Hayashi, H., Nakahara, S., Shimizu, W., Iwasaki, Y.-k., Fujimoto, Y., Mukai, Y., Ejima, K., Otsuka, T., Suzuki, S., Murakami, M., Kimura, M., Harada, M., Koyama, J., Okamatsu, H Tags: Open access, Cardiovascular medicine Source Type: research

Impact of atrial fibrillation type (paroxysmal vs. non-paroxysmal) on long-term clinical outcomes: The RAFFINE registry subanalysis
CONCLUSIONS: Non-paroxysmal AF was significantly associated with cardiovascular events. Long-term clinical outcomes might be improved if transition from paroxysmal to non-paroxysmal AF can be prevented.PMID:36640907 | DOI:10.1016/j.jjcc.2022.12.010
Source: Journal of Cardiology - January 14, 2023 Category: Cardiology Authors: Hideki Wada Katsumi Miyauchi Satoru Suwa Sakiko Miyazaki Hidemori Hayashi Kazuo Yamashiro Ryota Tanaka Yuji Nishizaki Shuko Nojiri Masataka Sumiyoshi Yuji Nakazato Takao Urabe Nobutaka Hattori Tohru Minamino Hiroyuki Daida Source Type: research